Consegna has sold its Linguet technology to Imugene; Intellipharmaceutics settles patent litigation with AstraZeneca;

> Consegna has sold its Linguet technology to Imugene in exchange for a 29% shareholding. Article

> Intellipharmaceutics has settled all outstanding patent litigation with AstraZeneca ($AZN) over the generic version of AZ's Seroquel XR, an extended-release formulation of quetiapine. Press release

> The FDA has accepted NuPathe's ($PATH) resubmission of Zelrix, its migraine patch; the target date for the FDA to complete its review of the NDA is Jan. 17. Press release

> BioAlliance Pharma has received a U.S. patent for Sitavig, a tablet that sticks to the upper gum and delivers acyclovir to treat recurrent cold sores (labial herpes). Article

> Laser-engineered dissolving microneedles could deliver nadroparin. Abstract

> BD Medical's new needle aims to improve performance and patient comfort. Press release

> Bio-Path has started enrollment of a fourth cohort of a Phase I trial of liposomal Grb-2 for leukemia. Press release

> Diabetology to develop oral insulin for India. Press release

And Finally… Alexza's ($ALXA) CEO has high expectations of receiving FDA approval for Adasuve, its inhaled antipsychotic. Article

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.